Mainz Biomed Regains Nasdaq Listing Compliance

TL;DR

Mainz Biomed is back in Nasdaq's good graces, no more delisting fears for now.

AI Summary

On January 27, 2025, Mainz Biomed N.V. announced it has regained compliance with all Nasdaq Capital Market listing requirements, specifically addressing the minimum equity requirement. This filing confirms the company's adherence to Nasdaq's standards.

Why It Matters

Regaining compliance with Nasdaq listing requirements is crucial for maintaining the company's stock trading on the exchange, ensuring liquidity and investor confidence.

Risk Assessment

Risk Level: low — The filing is a routine notification of compliance with exchange listing rules, indicating a positive resolution to a potential risk.

Key Players & Entities

• Mainz Biomed N.V. (company) — The company filing the report and announcing compliance.
• Nasdaq Capital Market (company) — The stock exchange where Mainz Biomed N.V. is listed and has regained compliance.
• January 27, 2025 (date) — The date of the press release announcing compliance.

FAQ

Filing Documents

• ea0228728-6k_mainzbio.htm (6-K) — 10KB
• ea022872801ex99-1_mainzbio.htm (EX-99.1) — 8KB
• ex99-1_001.jpg (GRAPHIC) — 5KB
• 0001213900-25-006734.txt ( ) — 27KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File No. 001-41010 MAINZ BIOMED N.V. (Translation of registrant’s name into English) Robert Koch Strasse 50 55129 Mainz Germany (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F Form 40-F INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K On January 27, 2025, Mainz Biomed N.V. (the “Company”) issued a press release titled “Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements” announcing that it has regained compliance with Nasdaq’s minimum equity requirement and is in compliance with all the Nasdaq listing requirements. A copy of this press release is furnished herewith as Exhibit 99.1. This current report on Form 6-K and the exhibit hereto are hereby incorporated by reference into our registration statement on Form F-3 (no. 333-269091) as well as our registration statement on Form S-8 (no. 333-273203), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.. Exhibit No. Exhibit 99.1 Press release titled: “Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements” 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 27, 2025 By: /s/ William J. Caragol Name: William J. Caragol Title Chief Financial Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR